Radioactive iodine therapy dose impact on recurrence and survival in N1 papillary thyroid cancer
Dosages of RAIT ≥ 150 mCi do not appear to provide additional benefit in reducing recurrence compared to doses <150 mCi for N1a or N1b PTC patients. No differences in mortality or immediate RAIT side effects were observed between the two dosing regimens; however, interpretation is limited by low event rates. Large randomized trials are needed for further individualized recommendations regarding optimal RAIT dosage in N1 PTC.
Authors
- Sapna Nagar
- Peter Czako
- Fionna Sun
- Diane Studzinski (ORCID: https://orcid.org/0000-0002-6602-9610)
- Morta Lapkus (ORCID: https://orcid.org/0000-0002-1257-4357)
- Jordan Reilly (ORCID: https://orcid.org/0000-0001-5414-1704)
- Kevin R. Ward (ORCID: https://orcid.org/0000-0001-5939-409X)
- Jacquelyn Pastewski (ORCID: https://orcid.org/0000-0001-9881-1896)
- Ryan T. Davis (ORCID: https://orcid.org/0000-0003-0036-4085)
- Rose E. Callahan (ORCID: https://orcid.org/0000-0003-1156-7240)
- Heba Elassar (ORCID: https://orcid.org/0000-0002-8485-5529)
- Elizabeth E. Odil
Institutions
- Oakland University (US)
- GTx (United States) (US)
- Beaumont Hospital, Royal Oak (US)
Publication Details
- Journal
- Nuclear Medicine Communications
- Published
- 2024-11-27
- DOI
- https://doi.org/10.1097/mnm.0000000000001936
- Primary Topic
- Thyroid Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00